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Abstract
Mesenchymal stromal cells (MSCs) are the leading cell candidates in the field of regenerative medicine. These cells have also
been successfully used to improve skeletal muscle repair/regeneration; however, the mechanisms responsible for their
beneficial effects remain to be clarified. On this basis, in the present study, we evaluated in a co-culture system, the ability of
bone-marrow MSCs to influence C2C12 myoblast behavior and analyzed the cross-talk between the two cell types at the
cellular and molecular level. We found that myoblast proliferation was greatly enhanced in the co-culture as judged by time
lapse videomicroscopy, cyclin A expression and EdU incorporation. Moreover, myoblasts immunomagnetically separated
from MSCs after co-culture expressed higher mRNA and protein levels of Notch-1, a key determinant of myoblast activation
and proliferation, as compared with the single culture. Notch-1 intracellular domain and nuclear localization of Hes-1, a
Notch-1 target gene, were also increased in the co-culture. Interestingly, the myoblastic response was mainly dependent on
the paracrine release of vascular endothelial growth factor (VEGF) by MSCs. Indeed, the addition of MSC-derived
conditioned medium (CM) to C2C12 cells yielded similar results as those observed in the co-culture and increased the
phosphorylation and expression levels of VEGFR. The treatment with the selective pharmacological VEGFR inhibitor,
KRN633, resulted in a marked attenuation of the receptor activation and concomitantly inhibited the effects of MSC-CM on
C2C12 cell growth and Notch-1 signaling. In conclusion, this study provides novel evidence for a role of MSCs in stimulating
myoblast cell proliferation and suggests that the functional interaction between the two cell types may be exploited for the
development of new and more efficient cell-based skeletal muscle repair strategies.
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Introduction
Skeletal muscle has a robust capacity of repair/regeneration in
response to injury or disease, relying in large part upon the
presence of a population of skeletal myoblast precursors, the
satellite cells, whose activation, re-entry the cell cycle and
differentiation require signals emanated by damaged fibers and
infiltrating inflammatory cells [1,2]. However, these cells are
relatively scarce within the skeletal muscle tissue, comprising about
1% to 5% of the total muscle nuclei, and are not able to be
recruited in large number at the site of tissue damage. Therefore,
during disease or other adverse conditions, the injured muscle is
replaced by a fibrotic scar which typically accompanies the muscle
decline and compromises its function. Because of their features,
satellite cells represent the obvious cellular candidate to target in
muscle regenerative medicine. There are, in fact, several studies in
the literature focusing on the identification of factors improving
the growth and regenerative potential of these cells in their
microenvironment [3] and there is a number of examples of
satellite cell transplantation for skeletal muscle regeneration [4–6].
However, the full potential of satellite-cell therapy is affected by
several limitations, including the high heterogeneity of this cell
population [7], the loss of their myogenic potential upon in vitro
expansion [6] and the predetermination dependent from the
source of muscle fibers [8,9]. This has shifted the attention to other
cell sources of non-myogenic origin as additional candidates for
skeletal muscle repair/regeneration. In this field, transplantation
of mesenchymal stromal cells (MSCs) in animal models of
myopathies, including the ischemic, atrophic and dystrophic
muscle, has been shown to remarkably improve the functional
recover of the injured tissue [10–12]. MSCs are a rare population
of cells that can be isolated from the bone marrow, adipose tissue
and many other regions of the body, rapidly expanded ex vivo and
utilized for experimental and clinical studies. They have the
potential to acquire lineage of any-mesenchymal-derived tissue in
vitro. Despite their plasticity, the participation of MSCs to new
skeletal muscle fiber formation is controversial [10,13,14];
emerging evidence from a variety of injured adult tissues indicates
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that their therapeutic effects occur without evidence of long-term
tissue engraftment [15–18]. Indeed, the functional improvements
in injured tissue seem to be primarily due to the secretion by the
transplanted MSCs of cytokines and growth factors with multiple
effects on the injured tissue, including modulation of inflammation
and immune reaction, positive remodeling, angiogenesis and
protection from apoptosis [19–21]. We have recently reported in a
co-culture system that MSCs support proliferation of neonatal
cardiomyocyte precursors through combined paracrine/juxtacrine
mechanisms [22], suggesting the potential ability of these cells to
determine the fate of local stem cells and augment the endogenous
repair of the damaged tissues.
In the present study, we further explored this issue by
investigating whether MSCs influenced the in vitro behavior of
skeletal myoblasts. Using a co-culture system of bone-marrow
MSCs and C2C12 cells, we provided novel experimental evidence
that MSCs could interact with the skeletal myoblasts by
stimulating their proliferation potential and underscored the
molecular and cellular mechanisms involved.
Figure 1. Effects of MSCs on myoblast cell growth and differentiation. Time lapse videoimaging of C2C12 cells in single (A) and co-culture
with Dil (red)-labeled MSCs (B). Quantitative analyses of C2C12 cell proliferation in the different experimental conditions (C). Note that the presence of
MSCs greatly enhances myoblast proliferation. D) Confocal immunofluorescence to detect myogenin (green) expression in C2C12 cells in single and
co-culture with Dil-labeled MSCs; the quantitative analysis is reported in the corresponding histogram. E) Phase contrast microscopy showing
myotube formation in single and co-cultured C2C12 cells; the quantitative analysis is reported in the corresponding histogram. The results of these
experiments clearly show that myogenin is up-regulated in the co-cultured C2C12 cells and that myoblasts are the only cell type to contain
myogenin+ nuclei. Also their tendency to fuse into multinucleated myotube is greater in the presence of MSCs. Data represent the results of at least
three independent experiments with similar results. C: *p,0.05 versus T0; up,0.05 versus the earlier time points; #p,0.05 versus single culture. D, E:
*p,0.05.
doi:10.1371/journal.pone.0037512.g001
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Materials and Methods
Ethics Statement
All animal manipulations were carried out according to the
European Community guidelines for animal care (DL 116/92,
application of the European Communities Council Directive of 24
November 1986; 86/609/EEC) and approved by the Committee
for Animal Care and Experimental Use of the University of
Florence. The ethical policy of the University of Florence
conforms to the Guide for the care and use of laboratory animals
of the U.S. National Institutes of Health (NIH Publication No. 85–
23, revised 1996; University of Florence assurance No. A5278-01).
The protocols were communicated to local authorities and to
Italian Ministry of the Health; according to the Italian law (Art.7/
D.lgs 116/92) such procedure doesn’t require Ministry authoriza-
tion. The animals were housed with free access to food and water
and maintained on a 12 h light/dark cycle at 22C room
temperature (RT). All efforts were made to minimize the animal
suffering and the number of animals sacrified. Animals were killed
by decapitation.
Cell Culture
Murine C2C12 skeletal myoblasts obtained from American Type
Culture Collection (ATCC, Manassas, VA, USA), were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1% penicillin/streptomycin (Sigma,
Milan, Italy) at 37uC in a humidified atmosphere of 5% CO2 till
reaching 80% confluence and then they were shifted in
differentiation medium (myoblast DM), containing 2% horse
serum (HS, Sigma) for 12, 24, 48, 72 h and 5 days.
Mouse bone marrow mesenchymal stromal cells (MSCs) were isolated
from femura and tibiae of male C2F1 mice, following the Dobson
procedure [23], expanded in vitro and characterized as reported
previously [22]. These cells were cultured in myoblast DM for
24 h and, in same experiments, the culture medium (MSC-
derived conditioned medium, MSC-CM) was harvested and used
for culturing C2C12 myoblasts for 24 h to assess MSC paracrine
effects.
Transgenic bone marrow green fluorescent protein (GFP)-labeled MSCs
were isolated from male GFP transgenic Lewis rats (RRRC,
Missouri, USA), expanded and characterized as described
previously [24]. GFP-labeled MSCs were analyzed for green
fluorescence intensity at different passages in culture as well as
for the expression of particular cell surface molecules using flow
cytometry procedures: CD45-CyChromeTM, CD11b-FITC (in
order to quantify hemopoietic-monocytic contamination), CD90-
PE, CD73-PE, CD44-PE (BD Pharmingen, San Diego, CA,
USA).
Co-cultures of C2C12 myoblasts and MSCs. C2C12 cells
were co-cultured with mouse MSCs or GFP-labeled MSCs at a 2:1
Figure 2. Assessment of myoblast cell proliferation by cyclin A expression. C2C12 cells in single and co-culture with Dil(red)- or GFP(green)-
labeled MSCs for 24 h were incubated with specific antibodies against cyclin A (green, A,B; red, D-G) and observed by confocal microscopy. Notably,
the cells with the higher immunofluorescence intensity are those located in close contact with MSCs. C) Quantitative analysis of the number of cells
positive for cyclin A. Data represent the results of at least three independent experiments with similar results. *p,0.05.
doi:10.1371/journal.pone.0037512.g002
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ratio for different times, from 6 h up to 5 days in myoblast DM.
Mouse MSCs in the co-cultures were identified by labeling with
the fluorescent VybrantTM Dil Cell-Labeling solutions (Molecular
Probes, Eugene, OR, USA) according to the manufacturer’s
instructions.
Cell Treatments
C2C12 cells were treated with an ATP competitive inhibitor of
VEGFR tyrosine kinase activity, KRN633 (IC50 = 170 nM, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) for 24 h, or with a
specific c-secretase inhibitor, DAPT for 24 h to inhibit Notch-1
activation (5 mM, stock 5 mM in dymethil sulfoxide, DMSO,
0.1%, Sigma), or with soluble Vascular Endothelial Growth
Factor, VEGF (2 ng/ml and 20 ng/ml, Sigma) for 24 h, 48 h and
5 days.
Time-lapse Videomicroscopy
The dynamic behavior of the single cultures and the co-cultures
were analyzed for 72 h by time-lapse videomicroscopy (1 frame/
min, exposure time 0.5 s) using an inverted phase-contrast and
fluorescence microscope (Nikon, Tokyo, Japan) equipped with a
10X objective and a cooled video camera equipped with a
motorized filter wheel and its dedicated digital recording software
(Chroma CX3, DTA, Cascina, Italy). Quantitative analysis of the
cell growth was performed by direct cell counting and expressed as
percentage increase.
EdU (5-ethynyl-29-deoxyuridine) Incorporation Assay
Cell proliferation was evaluated by the EdU proliferation assay
using the fluorescent Click-iTH EdU Cell Proliferation Assay
(Invitrogen Life Technologies, Grand Island, NY, USA) according
to manufacturer’s instructions. This assay is based on the
incorporation of the pyrimidine analogue EdU in place of
thymidine into newly synthesized DNA of replicating cells. Briefly,
cells grown on glass coverslips were incubated in the presence of
the provided solution of 10 mM EdU for 24 h. After that, the cells
were washed with PBS, fixed with 0.5% buffered paraformalde-
hyde (PFA) for 10 min at RT, permeabilized with cold acetone for
3 min and then incubated with the Alexa Fluor 488 EdU detection
solution for 30 min at RT, protected from light. After washing, the
coverslips containing the labeled cells were mounted with an
antifade mounting medium (Biomeda Gel mount, Electron
Microscopy Sciences, Foster City, CA) and observed under a
confocal Leica TCS SP5 microscope (Leica Microsystems,
Mannheim, Germany). The number of the cells with EdU positive
nuclei was evaluated in 10 random 140.000 mm2 square micro-
scopic fields (63X ocular) in each cell preparation and expressed as
percentage of the total cell number.
Morphological Analyses
Confocal immunofluorescence. The cells, grown on glass
coverslips were fixed with 0.5% buffered PFA for 10 min at RT.
After 3 min permeabilization with cold acetone, the fixed cells
were blocked with 0.5% Bovine Serum Albumine (BSA) and 3%
Figure 3. Notch-1 patway in differentiating C2C12 myoblasts. A,B) mRNA and protein expression of Notch-1 receptor and its ligand, Jagged
1, evaluated by RT-PCR (A) and Western Blotting (B) in C2C12 cells in single culture; densitometric analysis of the bands normalized to b-actin is
reported in the histograms. C,D) Hes-1 expression in cells treated with 5 mM DAPT, a pharmacological inhibitor of Notch-1 activation. Note that the
inhibition of Notch-1 expression (C) is capable of reducing the expression of Hes-1 at the mRNA (D) and protein levels (C). Data represent the results
of at least three independent experiments with similar results. A, B, *p,0.05 versus 2 h; #p,0.05 versus 24 h; up,0.05 versus 48 h.C,D, *p,0.05.
doi:10.1371/journal.pone.0037512.g003
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glycerol in PBS for 20 min and incubated overnight at 4uC with
the following antibodies: rabbit polyclonal anti-cyclin A (1:100;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse
monoclonal anti-myogenin (1:50; Sigma), rabbit monoclonal
anti-Notch-1 (1:200; Abcam, Cambridge, UK), rabbit polyclonal
anti-Hes1 (1:300; Millipore, Milan, Italy) and goat polyclonal anti-
VEGFR2 (Flk-1, 1:50; Abcam). The immunoreactions were
revealed by incubation with specific anti-mouse, anti-rabbit or
anti-goat Alexa Fluor 488 or 568-conjugated IgG (1:200;
Molecular Probes) for 1 h at RT. Negative controls were carried
Figure 4. MSCs induce Notch-1 and Hes-1 expression in C2C12 myoblasts. A) Flow cytometric analysis of CD34 and CD73 antigen
expression in MSCs and C2C12 cells in single cultures and in C2C12 myoblasts after isolation from MSCs in the co-culture by immunomagnetical
separation using anti CD34 and anti CD73 antibodies (CD34+ C2C12; CD73- C2C12). B,C) CD34+ C2C12 and CD73- C2C12 cells in co-culture
immunomagnetically isolated from MSCs were analyzed for the expression of Notch-1 and Hes-1 by RT-PCR (B) and Western Blotting (C). Note that
Notch-1 and Hes-1 expression is robustly induced in the myoblastic cells after co-culturing with MSCs as compared with the single culture.
Densitometric analysis of the bands normalized to b-actin is reported in the corresponding histograms. Data represent the results of at least three
independent experiments with similar results. *p,0.05.
doi:10.1371/journal.pone.0037512.g004
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out by replacing the primary antibodies with non immune serum;
cross-reactivity of the secondary antibodies was tested in control
experiments in which primary antibodies were omitted. After
washing, the coverslips containing the immunolabeled cells were
mounted with an antifade mounting medium (Biomeda Gel
mount) and observed under a confocal Leica TCS SP5 microscope
(Leica Microsystems) equipped with a HeNe/Ar laser source for
fluorescence measurements and with differential interference
contrast (DIC) optics. Observations were performed using a Leica
Plan Apo 63X/1.43NA oil immersion objective. Series of optical
sections (102461024 pixels each; pixel size 204.3 nm), were taken
through the depth of the cells at intervals of 0.4 mm. Images were
then projected onto a single ‘extended focus’ image. When needed,
a single optical fluorescent section and DIC images were merged
Figure 5. Notch-1 signaling is activated in C2C12 myoblasts upon co-culture with MSCs. Confocal immunofluorescence analysis of Notch-
1 (A-C) and Hes-1 (D-F) expression in C2C12 cells in single and co-culture with Dil(red)- or GFP(green)-labeled MSCs for 24 h. After the co-culture,
C2C12 cells reveal a stronger reactivity for the activated Notch-intracellular domain (Notch-ICD) and for Hes-1, which is visible inside the nucleus. As
shown in the inserts, Notch-1 is preferentially located at the cell membrane (arrows) in the single cultured C2C12 cells, whereas it is found within the
cytoplasm (white arrowheads) and nucleus (grey arrowheads) in the co-cultured cells. E) C2C12 myoblast were treated with 5 mM DAPT to inhibit
Notch-1 activation and assayed for Hes-1 expression. The corresponding quantitative analysis is reported in the histograms (G,H). Data represent the
results of at least three independent experiments with similar results. *p,0.05.
doi:10.1371/journal.pone.0037512.g005
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Figure 6. MSCs influence C2C12 myoblast proliferation through paracrine mechanisms. C2C12 cells were grown in single culture (C2C12)
or exposed to MSC-derived CM (C2C12/MSC-CM) and their proliferative activity assessed by time lapse videomicroscopy (A-C), EdU (green)
incorporation (D, E), Notch-1 and Hes-1 expression by RT-PCR (F), Western blotting (G) and confocal immunofluorescence (H). Quantitative analyses of
the results shown are reported in the histograms. Data represent the results of at least three independent experiments with similar results. * p,0.05
versus T0; u p,0.05 versus the earlier time points; 1 p,0.05 vs 9 h; # p,0.05 versus single culture. D,E: * p,0.05.
doi:10.1371/journal.pone.0037512.g006
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to view the precise distribution of the immunostaining. Quanti-
fication of cyclin A, myogenin and Notch-1 expression was
performed on digitized images by counting the number of positive
cells over the total cell number. Densitometric analysis of the
intensity of Hes-1 fluorescent signal was performed on digitized
images using ImageJ software (http://rsbweb.nih.gov/ij) in 20
regions of interest (ROI) of 100 mm2 for each confocal stack (at
least 10).
Phase contrast microscopy. Myotube formation was as-
sayed in 10 random 1.200.000 mm2 optical square fields (20X)
under an inverted phase contrast microscopy (Nikon Diaphot 300)
in each cell preparation.
Flow Cytometry
Flow cytometry assay was used to distinguish the two cell
populations on the basis of their cell surface antigen expression. To
this aim, MSCs and C2C12 cells recovered from flask by trypsin-
Ethylenediaminetetraacetic acid (EDTA) treatment, were re-
suspended in flow cytometry buffer consisting of CellWASH
(0.1% sodium azide in PBS; Becton Dickinson, San Jose, CA,
Figure 7. MSCs influence C2C12 myoblast proliferation through the release of VEGF. A) Cytokine and growth factor secretion profiles by
MSCs grown in C2C12 differentiation medium (MSC-CM). B) Western Blotting analysis of VEGFR2 expression in C2C12 cells in single culture (C2C12) or
exposed to MSC-CM (C2C12/MSC-CM), in the presence or absence of VEGFR2 inhibitor, KRN633. C) Superimposed DIC and fluorescence image
showing cellular localization of VEGFR2 in C2C12 cells; the staining (green) is mainly localized at the cell surface. D) VEGFR2 phosphorylation in C2C12
cells in the noted experimental conditions, assayed by Western Blotting analysis performed on the immunoprecipitated VEGFR2 protein. Note that
VEGFR2 expression and phosphorylation levels increase in the cells exposed to MSC-CM as compared with control. E) Superimposed DIC and
fluorescence image showing nuclear EdU (green) staining and corresponding quantitative analysis. (F,G) Notch-1 expression by (F) Western blotting
and (G) confocal immunofluorescence in C2C12 cells in the indicated experimental conditions. The quantitative analyses are reported in the
histograms. Note that EdU staining and Notch-1 expression are significantly affected by treatment with the VEGFR2 inhibitor, KRN633. Data represent
the results of at least three independent experiments with similar results. * p,0.05.
doi:10.1371/journal.pone.0037512.g007
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USA) with 2% FBS and incubated with FITC-or PE- conjugated
monoclonal antibodies (BD Pharmingen, San Diego, CA, USA)
against myoblastic (CD34) and mesenchymal (CD73) cell marker
[22,25]; 7-aminoactinomycin AAD (7-AAD, BD Pharmingen) was
added in order to exclude dead cells from the analysis. Flow
cytometric acquisition was performed by collecting 104 events on a
FACScalibur (Becton Dickinson) instrument and data were
analyzed on DOT-PLOT bi-parametric diagrams using CELL
QUESTPRO software (Becton Dickinson, San Jose, CA, USA) on
Macintosh PC.
Immunomagnetic Cell Separation
C2C12 myoblasts and MSCs were separated after 24 h co-
culture using MACS micro beads technology (Miltenyi Biotec,
Bologna, Italy). In particular, the co-cultured cells were recovered
by trypsin-EDTA treatment resuspended in Buffer containing
0.5% BSA and 2 mM EDTA and incubated with CD73 or CD34
PE-conjugated antibody (BD Pharmingen) following manufactur-
er’s instructions. Cells were then incubated with anti-PE MicroBe-
ads and separated on MS MACS column following manufacturer’s
instructions (Miltenyi Biotec). The positive and negative cell
fractions were then analyzed by flow cytometry and processed for
Western Blotting and RT-PCR analysis. C2C12 cells in single
culture were subjected to the same treatments of those in co-
culture and used as control.
Total RNA Extraction and Reverse Transcription (RT)-PCR
Expression levels of mRNA of Notch-1, Jagged-1 and Hes-1
were assayed by RT-PCR. Total RNA was isolated by extraction
with TRIzol Reagent (Invitrogen), according to the manufactur-
er’s instructions. One mg of total RNA were reverse transcribed
and amplified with SuperScript One-Step RT-PCR System
(Invitrogen). The following mouse gene-specific primers were
used: Notch-1 (NM_008714.3), forward 59-GTC CCA CCC ATG
ACC ACT AC-39 and reverse 59-CCT GAA GCA CTG GAA
AGG AC-39; Jagged-1 (NM_013822.4), forward 59-CAG GAC
ACA CAA CTC GGA AG-39 and reverse 59-CCA GCC AAC
CAC AGA AAC TAC-39; Hes-1 (NM_ 008235), forward 59-AAT
TTG CCT TTC TCA TCC CCA-39 and reverse 59- CAG TCA
CTT AAT ACA GCT CTC-39 b-actin (NM_007393.3), forward
Figure 8. Effects of soluble VEGF on C2C12 myoblast proliferation and differentiation. C2C12 cells in single culture were treated with
different concentrations of soluble VEGF and assayed for Notch-1 and Hes-1 expression by RT-PCR (A), myogenin expression (green) by confocal
immunofluorescence (B), and for myotube formation by phase contrast microscopy (C). The quantitative analyses are reported in the histograms.
Data represent the results of at least three independent experiments with similar results.* p,0.05.
doi:10.1371/journal.pone.0037512.g008
MSC/Skeletal Myoblast Functional Interaction
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e37512
59-ACT GGG ACG ACA TGG AGA AG-39 and reverse 59-
ACC AGA GGC ATA CAG GGA CA-39. b-actin mRNA was
used as internal standard. Blank controls, consisting in no template
(water), were performed in each run. PCR products were
separated by electrophoresis on a 2% agarose gel and the
ethidium bromide-stained bands were quantified by densitometric
analysis by using the Scion Image Beta 4.0.2 image analysis
program (Scion Corp., Frederick, MD, USA). b-actin normaliza-
tion was performed for each result.
Western Blotting
Cells were resuspended in appropriate volume of cold lysis
buffer: 10 mmol/L Tris/HCl, pH 7.4, 10 mmol/L NaCl,
1.5 mmol/L MgCl2, 1% Triton X-100, 2 mmol/L Na2EDTA,
added with 106 Sigmafast Protease Inhibitor cocktail tablets
(Sigma). Upon centrifugation at 13.000 g for 15 min at 4uC, the
supernatants were collected and the total protein content was
measured spectrophotometrically using micro-BCATM Protein
Assay Kit (Pierce, IL, USA). Forty mg of total proteins were
electrophoresed by SDS-PAGE (200V, 1 h) using a denaturating
7.6% polyacrylamide gel and blotted onto nitrocellulose mem-
branes (Amersham, Cologno Monzese, Italy; 150V, 1 h). The
membranes were blocked with PBS containing 0.1% Tween
(Sigma) and 5% bovine serum albumin (AT-PBS) (Sigma) for 1 h
at RT and incubated overnight at 4uC with rabbit monoclonal
anti-Notch-1 antibody (1:2000 in AT-PBS; Abcam) goat poly-
clonal anti-Jagged-1 antibody (1:1000 in AT-PBS; Santa Cruz
Biotechnology), rabbit polyclonal anti-Hes-1 (1:20.000 in AT-PBS
Millipore) and goat polyclonal anti-VEGFR2 (Flk-1) (1:1000 in
AT-TBS; Abcam). Membranes were also immunostained with
rabbit polyclonal anti-b-actin antibody (1:20.000 in AT-PBS;
Sigma), assuming b -actin as control invariant protein. After
washing, the membranes were incubated with peroxidase-labeled
anti-rabbit or anti-goat antibodies (1:15.000 in AT-PBS; Vector,
Burlingame, CA, USA) for 1 h at RT and the immunoreactivity
was detected by the ECL chemiluminescent substrate (Amersham).
Densitometric analysis of the bands was performed using Scion
Image Beta 4.0.2 image analysis software (Scion Corp.) and the
values normalized to b-actin.
Immunoprecipitation
The cells were lysed as reported previously [26]. One mg of
whole cell extract was pre-cleared by Protein A/G Plus-Agarose
(Santa Cruz Biotechnology) for 1 h at 4uC. After centrifugation,
the supernatants were collected and incubated overnight at 4uC
with gentle inverting, with 4 mg of goat polyclonal anti-
VEGFR2(Flk-1) antibody (Abcam). Then the samples were re-
incubated with Protein A/G Plus-Agarose for 2 h at 4uC and
precipitated by centrifugation. Complexes were subjected to
electrophoresis and blotted with mouse monoclonal anti-phos-
pho-tyrosine antibody (1:1000 in AT-TBS; Sigma) and then re-
probed with anti- VEGFR2(Flk-1) antibody.
Cytokine/growth Factor Assay
Interleukin (IL)-15, IL-18, basic fibroblast growth factor
(bFGF), leukemia inhibiting factor (LIF), macrophage colony
stimulating factor (M-CFS), interferon-c-induced monokine
(MIG), macrophage inflammation protein (MIP)-2 and VEGF-
1 levels were measured in MSC-CM by using Bio-Plex Pro
Mouse Cytokine assay (Bio Rad Laboratories Inc., Hercules,
CA, USA) following the manufacturer’s instructions essentially
as described previously [22].
Statistical Analysis
Data were reported as mean 6 SEM and the statistical
significance was determined by one-way ANOVA and Newman-
Keuls multiple comparison test or Student’s t test. A p value #0.05
was considered significant. Calculations were performed using-
GraphPad Prism software (GraphPad, San Diego, CA, USA).
Results
MSCs Stimulate C2C12 Cell Proliferation
To examine whether myoblast proliferation was modulated
by interactions with MSCs, we used a model of direct co-
culture of native C2C12 cells and MSCs marked with Dil (Dil-
MSCs), in order to distinguish the behavior of the two cell
types. Time-lapse videoimaging and cell counting showed that
the co-presence of MSCs significantly enhanced C2C12 cell
proliferation, since the early times of co-cultures (from 6 h up to
48 h) (Fig. 1A–C). MSCs also proliferated, although at a
markedly lower rate than the adjacent C2C12 cells (1% increase
after 24 h), and established transient cell-cell-contacts with
C2C12 cells (Fig. 1B). In the co-culture, myoblast proliferation
gradually decreased after 24 h and became negligible after 72 h;
whereas in the single culture, the cells continued to actively
proliferate up to 48 h (Fig. 1C). Increased myoblast proliferation
in the co-culture with MSCs was associated with increased
myoblast differentiation, as judged by the analysis of the
expression of myogenin, a key myogenic differentiation factor,
(Fig. 1D), and by the tendency of the cells to form
multinucleated myotubes at longer time points (5 days)
(Fig. 1E). MSCs in the co-culture failed to express myogenic
markers, such as myogenin, or fuse with differentiating
myoblasts (data not shown), indicating that these cells were
unable to trans-differentiate along the myoblastic lineage in our
experimental conditions. The ability of MSCs to potentiate
C2C12 myoblast proliferation was further confirmed by the
findings of increased EdU incorporation (83.368% and
63.365% of the myoblasts resulted EdU positive in the co-
cultures and single culture, respectively, p,0.05 by Student’s
Test) and cyclin A nuclear and cytoplasmic expression in the
myoblasts co-cultured for 24 h with either Dil- (Fig. 2A–C) or
GFP-MSCs (Fig. 2 D–G) as compared to those in the single
culture.
To unveil the molecular mechanisms underlying the stimulatory
effects of MSCs on C2C12 cell proliferation, we investigated the
involvement of Notch-1, a key determinant of myoblast activation
and skeletal muscle regeneration [27]. We first showed that Notch-
1 and its ligand Jagged-1 were expressed at high levels in
differentiating C2C12 cells as judged by RT-PCR and Western
blotting; in particular, while the levels of Notch-1 and Jagged-1
mRNA remained practically costant during the whole period of
differentiation, the expression of the corresponding proteins
reached the maximal values in the early stages (24 h for Notch-1
and 48 for Jagged-1), in coincidence with the higher proliferative
activity (Fig. 3A,B). Although the reasons for this discrepancy is
not known, it is possible that the regulation of Notch-1 pathway
may follow distint pathway at the mRNA and protein levels in our
cell system. We also showed that the treatment of C2C12 cells with
a specific pharmacological inhibitor of Notch-1 activation, DAPT,
was able to affect the expression of Hes-1 at the mRNA and
protein levels (Fig. 3C,D; Fig. 5E,H), thus confirming its role as a
target gene of Notch-1 action.
To isolate myoblasts from MSCs after co-culture, the cells
were first assayed by flow cytometry to identify cell surface
markers selectively expressed by one or the other cell types. We
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found that CD34 was expressed on C2C12 cells while was
absent in MSCs, whereas the mesenchymal CD73 marker was
present at high levels only in MSCs (Fig. 4A, upper panels; cell
viability .90%). The cells in co-culture were then immuno-
magnetically separated using anti-CD34 and anti-CD73 PE-
conjugated antibodies and anti-PE MicroBeads, and the
recovered C2C12 cell fraction (Fig. 4A lower panels),
CD34+(mean purity 9862% and cell viability 9067.2%) and
CD73- (mean purity 80.063% and cell viability 91.369.0%)
were processed for total RNA and protein extraction. The
results showed that 24 h of co-culture stimulated Notch-1
expression at the mRNA and protein levels in the myoblastic
cells (Fig. 4B,C). The mRNA levels of Hes-1 were also up-
regulated in the co-culture (Fig. 4B). By confocal microscopy,
using a specific antiserum recognizing both Notch-1 receptor
and its activated form, Notch-1 intracellular domain (Notch-
ICD), we observed that co-cultured C2C12 cells expressed
higher levels of cytoplasmic and nuclear Notch-ICD as
compared with control cells (Fig. 5A–C,G). Moreover, it was
possible to detect that the expression of Hes-1, increased in the
co-cultured myoblasts and was predominantly localized within
the nuclei (Fig. 5D–F,H).
MSCs Influence C2C12 Cell Proliferation Through
Paracrine Mechanisms
To discriminate the mechanisms underlying C2C12-MSC cell
interaction, C2C12 myoblasts were cultured with MSC-CM for
24 h. Of interest, the stimulatory effect of MSC-CM on C2C12
cell growth approximated that of the co-cultures as judged by
Time-lapse (Fig. 6A–C) and EdU incorporation (Fig. 6D,E)
revealing that factors secreted by MSCs were mainly responsible
for the observed enhancement of myoblast proliferation in the
co-culture system. Consistent with this finding, the treatment
with MSC-CM yielded similar results in term of Notch-1 and
Hes-1 expression (Fig. 6F–H), thus suggesting that MSCs in co-
culture behave as stromal supporting cells to positively influence
the expansion of skeletal myoblasts in a paracrine manner. In
order to better investigate this interaction, we searched for
signals emanating from MSCs that could influence myoblast
proliferation. We found that MSC-CM contained significant
amount of cytokines and growth factors, particularly VEGF
(Fig. 7A), whose signal potential has been previously shown to
occur through Notch-1 pathway [28]. We, therefore, asked
whether VEGF activity was required for MSCs to influence
C2C12 cell growth. Our results showed that VEGFR2 (Flk-1),
the major mediator of myoblast cell proliferation in response to
VEGF [29], was expressed by C2C12 cells (Fig. 7B,C). By
Western blot analysis with an anti-phospho-tyrosine antibody
performed on the immunoprecipitated VEGFR2 (Flk-1) protein,
we found that the levels of VEGFR2 tyrosine phosphorylation
were significantly increased in the myoblastic cells cultured in
MSC-CM as compared to controls (Fig. 7D). Interestingly, the
treatment with the selective pharmacological VEGFR2 inhibitor,
KRN633, markedly attenuated the receptor phosphorylation
without modifying its expression (Fig. 7B, D) and reduced the
effects of MSC–CM on Notch-1 activation and EdU incorpo-
ration (Fig. 7E–G) in C2C12 cells, demonstrating that VEGF
could mediate the paracrine effects of MSCs on myoblast
proliferation. Interestingly, the findings that VEGFR2 expres-
sion levels were increased in the C2C12 cells stimulated with
MSC-CM (Fig. 7B) indicated that secreted factors by MSCs
could also be able to modulate VEGF responsiveness in these
cells.
Finally, the role of VEGF in C2C12 myoblast proliferation and
differentiation was further assayed in experiments in which the
single cultured cells were exposed to different concentrations
(2 ng/ml and 20 ng/ml) of soluble VEGF (Fig. 8). As expected,
the treatments stimulated both the expression of Notch-1 and Hes-
1 within the first 24 h, and of myogenin in the later times (48 h) as
well as increased the tendency of the myoblasts to fuse into
multinucleated myotubes (5 days).
Discussion
Growing evidence suggests that MSCs are attractive candidates
for cell-based therapy in regenerative medicine, thanks to their
trophic activity and immunosuppressive properties, which allow
them to be used in different clinical contexts [19,21]. In the
present study, we offer evidence that these cells can establish
complex paracrine interactions with skeletal myoblasts and
stimulate their proliferation and differentiation through the up-
regulation of Notch-1 signaling, a key regulator of muscle
progenitor cell proliferation and myogenesis [27,30]. In such a
view, our data extend previous observations from our group on the
remarkable ability of MSCs to engage in cross talk with stem/
precursor cells [22] and provide novel clues for a role of these cells
in the stimulation of the endogenous skeletal muscle repair/
regeneration. In this line of thought, it is worth of noting that a
close relationship between stromal and satellite cells has been
shown within the skeletal muscle niche and a role for the stromal
cells as a natural scaffold on which stem cells interact and
proliferate, has been proposed [31], thus supporting the instructive
potential of MSCs for the recruitment of the intrinsic muscle stem
cell pool.
We have also shown that MSCs contributed to myoblast
proliferation through the released of VEGF, on the basis that
VEGFR2 showed increased tyrosine phosphorylation in C2C12
cells cultured in MSC-derived CM and that its specific pharma-
cological inhibition was able to significantly reduce the effects of
this medium on C2C12 cell proliferation and Notch-1 activation.
Of interest, VEGFR2 expression levels were dependent on the
ligand availability, since they increased significantly in the cells
stimulated with MSC-CM. Since previous observation have
demonstrated that VEGF regulates VEGFR2 transcription by a
positive feedback loop through its promoter region [32–34], it is
possible that MSCs may be able not only to activate VEGF
signaling, but also to modulate its responsiveness in the myoblastic
cells.
Although VEGF has been originally described as a crucial
regulator of vascular development during embryogenesis and
blood vessel formation in adult life, there is evidence suggesting
that its effects may extend to a variety of other cell types,
including myoblast and skeletal muscle fibers [29,35,36].
However, despite the emerging concept that satellite and
endothelial cells co-operatively interact during angio-myogenesis
[37,38] and that VEGF plays an essential role in this
bidirectional interaction [39], the involvement of this growth
factor on muscle repair/regeneration has been poorly charac-
terized. Of interest, recent observations show that VEGF is up-
regulated in hypertrophic and hypoxic myofibres [40,41],
providing the basis for considering VEGF as a multifaceted
factor for muscle growth and survival. In such a view, our data
contribute to acknowledge the role of this growth factor in
skeletal muscle tissue and open the interesting possibility that
MSCs, through the sustained secretion of VEGF, may serve to
structure a regenerative microenvironment for damaged skeletal
muscle, stimulating myoblast proliferation in concert with neo-
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angiogenesis. It could be expected that the combination of
MSCs with tissue engineering technology, involving the use of
tissue-specific scaffolds to prolong the survival and integration of
the encased MSCs at the implantation sites, may greatly
improve the therapeutic potentials of these cells and subsequent
regeneration of skeletal muscle. Experiments are ongoing in our
lab to test this hypothesis.
In conclusion, we have demonstrated that MSCs support
myoblast proliferation and accelerate their differentiation, and
underscored the cellular and molecular cross-talk between the
two cell types. We also offer circumstantial evidence that the
secretion of VEGF by MSCs may be one of the potential
mechanism through which these cells influence the fate of
skeletal myoblasts and provide experimental background for
considering these cells as potential valid therapeutic tools for
skeletal muscle disease.
The advantage of using MSC-based cell therapy over the
exogenously administered VEGF may rely on the possibility to
obtain local, constant and biologically effective levels of this
growth factor in the contest of the regenerating muscle and to
modulate and integrate its action with those of the other paracrine
factors released in situ by the engrafted cells.
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